Intravenous Hydroxypropyl β-Cyclodextrin Formulation of Letermovir: A Phase I, Randomized, Single-Ascending, and Multiple-Dose Trial

Clinical and Translational Science

Volumn 10, Issue 6, 2017, Pages 487-495

  Erb Zohar, K ^a   Kropeit, D ^b   Scheuenpflug, J ^c   Stobernack, H P ^b   Hulskotte, E G J ^d   van Schanke, A ^e   Zimmermann, H ^b   Rubsamen Schaeff H ^b  

^a Clinphase   (Germany)

^b AiCuris GmbH   (Germany)

^c MERCK KGAA   (Germany)

^d NV ORGANON   (Netherlands)

^e Quantitative Solutions BV   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; LETERMOVIR; PLACEBO; ACETIC ACID DERIVATIVE; QUINAZOLINE DERIVATIVE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BODY MASS; COHORT ANALYSIS; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DOUBLE BLIND PROCEDURE; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; INFORMED CONSENT; INFUSION RELATED REACTION; INJECTION SITE BLEEDING; INJECTION SITE PAIN; INJECTION SITE REACTION; NAUSEA; NECK PAIN; PHLEBITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; THROMBOPHLEBITIS; VESSEL PUNCTURE SITE HEMATOMA; VESSEL PUNCTURE SITE PAIN; VESSEL PUNCTURE SITE REACTION; VOMITING; BLOOD; CHEMISTRY; CLINICAL TRIAL; DEMOGRAPHY; DOSE RESPONSE; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; PHASE 1 CLINICAL TRIAL; TIME FACTOR; VISUAL ANALOG SCALE; YOUNG ADULT;

2-HYDROXYPROPYL-BETA-CYCLODEXTRIN; ACETATES; ADMINISTRATION, INTRAVENOUS; ADULT; AREA UNDER CURVE; DEMOGRAPHY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MIDDLE AGED; QUINAZOLINES; TIME FACTORS; VISUAL ANALOG SCALE; YOUNG ADULT;

EID: 85021814960     PISSN: 17528054     EISSN: 17528062     Source Type: Journal    
DOI: 10.1111/cts.12483     Document Type: Article

References (16)

1. Ljungman, P., Hakki, M. & Boeckh, M. Cytomegalovirus in hematopoietic stem cell transplant recipients. Infect. Dis. Clin. North Am. 24, 319–337 (2010).
2. Ahmed, A. Antiviral treatment of cytomegalovirus infection. Infect. Disord. Drug Targets 11, 475–503 (2011).
3. Marty, F.M. et al. Brincidofovir for prevention of cytomegalovirus (CMV) after allogeneic hematopoietic cell transplantation (HCT) in CMV-seropositive patients: a randomized, double-blind, placebo-controlled, parallel-group phase 3 trial. Biol. Blood Marrow Transplant. 22 (Suppl), S23 (2016).
4. Winston, D.J. et al. Efficacy and safety of maribavir dosed at 100 mg orally twice daily for the prevention of cytomegalovirus disease in liver transplant recipients: a randomized, double-blind, multicenter controlled trial. Am. J. Transplant. 12, 3021–3030 (2012).
5. Zimmermann, H., Lischka, P. & Ruebsamen-Schaeff, H. Letermovir (AIC246) a novel drug under development for prevention and treatment of cytomegalovirus infections acting via a novel mechanism of action. Eur. Infect. Dis. 5, 112–114 (2011).
6. Goldner, T., Hewlett, G., Ettischer, N., Ruebsamen-Schaeff, H., Zimmermann, H. & Lischka, P. The novel anticytomegalovirus compound AIC246 (Letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase. J. Virol. 85, 10884–10893 (2011).
7. Lischka, P. et al. In vitro and in vivo activities of the novel anticytomegalovirus compound AIC246. Antimicrob. Agents Chemother. 54, 1290–1297 (2010).
8. Reefschlaeger, J. et al. Novel non-nucleoside inhibitors of cytomegaloviruses (BAY 38-4766): in vitro and in vivo antiviral activity and mechanism of action. J. Antimicrob. Chemother. 48, 757–767 (2001).
9. Buerger, I. et al. A novel nonnucleoside inhibitor specifically targets cytomegalovirus DNA maturation via the UL89 and UL56 gene products. J. Virol. 75, 9077–9086 (2001).
10. Sullivan, V., Talarico, C.L., Stanat, S.C., Davis, M., Coen, D.M. & Biron, K.K. A protein kinase homologue controls phosphorylation of ganciclovir in human cytomegalovirus-infected cells. Nature 358, 162–164 (1992).
11. Chemaly, R.F. et al. Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation. N. Engl. J. Med. 370, 1781–1789 (2014).
12. Stoelben, S. et al. Preemptive treatment of cytomegalovirus infection in kidney transplant recipients with letermovir: results of a phase 2a study. Transpl. Int. 27, 77–86 (2014).
13. Kaul, D.R. et al. First report of successful treatment of multidrug-resistant cytomegalovirus disease with the novel anti-CMV compound AIC246. Am. J. Transplant. 11, 1079–1084 (2011).
14. Merck & Co. Inc. Kenilworth, NJ, USA. Merck's letermovir, an investigational antiviral medicine for prevention of cytomegalovirus (CMV). Infection in bone marrow transplant recipients, highly effective through week 24 post-transplant in pivotal phase 3 study. http://www.mercknewsroom.com/news-release/research-and-development-news/mercks-letermovir-investigational-antiviral-medicine-prev (2017).
15. European Medicines Agency (EMA). Background review for cyclodextrins used as excipients. http://www.ema.europa.eu/docs/en_GB/document_library/Report/2014/12/WC500177936.pdf Last updated 20 November 2014; Accessed 6 June 2016.
16. Jackson, A. Infection control–a battle in vein: infusion phlebitis. Nurs. Times 94, 68, 71 (1998).